Withus Pharmaceutical Co Ltd
KOSDAQ:330350
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (10.5), the stock would be worth ₩6 998.48 (29% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 14.8 | ₩9 810 |
0%
|
| 3-Year Average | 10.5 | ₩6 998.48 |
-29%
|
| 5-Year Average | 12.9 | ₩8 604.95 |
-12%
|
| Industry Average | 16.8 | ₩11 189.33 |
+14%
|
| Country Average | 8.5 | ₩5 676.15 |
-42%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
W
|
Withus Pharmaceutical Co Ltd
KOSDAQ:330350
|
129.5B KRW | 14.8 | 20.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 28.5 | 42.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 16.6 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.6 | 19.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 16.2 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 12.4 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 9.6 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8 | 10.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 7.6 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.4B USD | 7.1 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 5.3 |
| Median | 8.5 |
| 70th Percentile | 15.6 |
| Max | 24 013.5 |
Other Multiples
Withus Pharmaceutical Co Ltd
Glance View
Withus Pharmaceutical Co., Ltd. manufactures and sells prescription drugs. The company is headquartered in Seoul, Seoul and currently employs 217 full-time employees. The company went IPO on 2020-07-03. The firm's main products include circulatory agents, musculoskeletal agents, digestive agents, antibiotics and other prescription drugs. And the Company is engaged in contract manufacturing operation(CMO).
